DAFNA Capital Management LLC lifted its stake in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 35.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 266,500 shares of the biopharmaceutical company’s stock after buying an additional 70,000 shares during the quarter. DAFNA Capital Management LLC owned approximately 0.19% of Achillion Pharmaceuticals worth $1,223,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of Achillion Pharmaceuticals by 51.1% during the first quarter. Dimensional Fund Advisors LP now owns 613,006 shares of the biopharmaceutical company’s stock worth $2,581,000 after buying an additional 207,204 shares in the last quarter. Deschutes Portfolio Strategy LLC grew its position in shares of Achillion Pharmaceuticals by 358.6% during the second quarter. Deschutes Portfolio Strategy LLC now owns 116,630 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 91,200 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in shares of Achillion Pharmaceuticals during the first quarter worth about $149,000. Senzar Asset Management LLC acquired a new position in shares of Achillion Pharmaceuticals during the second quarter worth about $4,966,000. Finally, Wells Fargo & Company MN grew its position in shares of Achillion Pharmaceuticals by 11.9% during the first quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock worth $908,000 after buying an additional 22,931 shares in the last quarter. 74.11% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently issued reports on ACHN. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Robert W. Baird reaffirmed a “neutral” rating and issued a $4.00 price target (down from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Chardan Capital lowered their price target on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, August 9th. ValuEngine downgraded Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Monday, September 11th. Finally, Maxim Group set a $7.00 price target on Achillion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $6.75.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) traded up 3.10% during trading on Thursday, reaching $4.66. The company had a trading volume of 394,742 shares. The firm has a 50-day moving average price of $4.49 and a 200-day moving average price of $4.22. Achillion Pharmaceuticals, Inc. has a 52-week low of $3.15 and a 52-week high of $8.08. The company’s market capitalization is $637.31 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). During the same period in the previous year, the company earned ($0.14) EPS. On average, analysts predict that Achillion Pharmaceuticals, Inc. will post ($0.66) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/10/05/dafna-capital-management-llc-has-1-22-million-stake-in-achillion-pharmaceuticals-inc-achn.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.